Moderna stock soars 177%, Merck jumps 12% after cancer vaccine shows promise in late-stage trial
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
